MANAGEMENT PRESENTATION - Monica Wallter, CEO - Lidds

Page created by Dorothy Mason
 
CONTINUE READING
MANAGEMENT PRESENTATION - Monica Wallter, CEO - Lidds
MANAGEMENT PRESENTATION
    Monica Wallter, CEO
    monica.wallter@liddspharma.com
1
                                     November 2018
MANAGEMENT PRESENTATION - Monica Wallter, CEO - Lidds
Table of content

                       1.   Introduction to LIDDS

                       2.   NanoZolid® with 2-HOF – Prostate cancer

                       3.   NanoZolid® with cytostatics (DTX)

                       4.   NanoZolid® for immunotherapy (IO)

                       5.   NanoZolid® with STING-agonist

                       6.   NanoZolid® with TLR9 agonist

                       A.   Appendix
2
MANAGEMENT PRESENTATION - Monica Wallter, CEO - Lidds
Unique and patented technology platform

                               in brief
                                                                           ONE PLATFORM                     PROJECTS
      LIDDS is a Swedish-based pharmaceutical company developing
    injectable drugs for cancer and other diseases based on our unique
    proprietary NanoZolid® technology. NanoZolid® helps solve some of
                                                                                          Combined with anti-androgen
                                                                                          Liproca® Depot for treatment of localized
    the main problems with the way drugs work in the body and which
                                                                                          prostate cancer
                        affect patient quality of life.                                   Status: Phase IIb

    NanoZolid® enables the controlled, long-term release of drugs for up
                                                                                          Combined with cytostatic
    to six months. NanoZolid® can be combined with traditional small as
                                                                                          NanoZolid® combined with Docetaxel (DTX)
                       well as with larger molecules.                                     Status: Phase I study started Q1 2019

    LIDDS has licensing agreements where NanoZolid® is combined with
     antiandrogens and in-house development in pre-clinical projects in                   Combined with TLR9-agonist
          clinical phase for cytostatics and immunoactive agents.                         NanoZolid® combined with TLR9-agonists
                                                                                          Status: Pre-clinical full program ongoing

       Founded                                                  2003                      Combined with STING-agonist
                                                                                          NanoZolid® combined with STING-agonists (STING)
                                                                                          Status: Pre-clinical full program ongoing
       HQ                                        Uppsala, Sweden

       Employees                                                 ~10
                                                                                          Combined with immunotherapy
                                                                                          NanoZolid® combined with a range of IO agents in
                                                                                          development
       Listing venue                           Nasdaq First North                         Status: Ongoing preclinical package

3
MANAGEMENT PRESENTATION - Monica Wallter, CEO - Lidds
NanoZolid® is an innovative drug delivery platform
                                                 IDEAL DRUG DELIVERY PROPERTIES

    ▪    NanoZolid® is a safe, flexible and functional method of delivering drugs.

    ▪    NanoZolid® provides effective, controlled and tailor made release of drugs with small or larger size.

    ▪    NanoZolid® has a broad drug formulation capability and can be formulated with substances of very different
         molecular characteristics.

    ▪    The NanoZolid® matrix with drug is reabsorbed completely in the tissue due to its water solubility.

        THE CONTROLLED RELEASE OF DRUG COMPOUNDS CAN BE TAILORED TO THE NEEDS OF THE PATIENT, DISEASE AND DRUGS BEING USED:
MANAGEMENT PRESENTATION - Monica Wallter, CEO - Lidds
The platform can be used for a wide range of applications
    NanoZolid® has many applications and can be tailored to the needs of the patient, the disease being
    treated and the drug formulations being used.

                         Intratumorally
                         NanoZolid® provides a high level of efficiency by allowing cancer drugs to be
                         injected directly into the tumor.
                         Controlled release results in higher local impact and reduced severe systematic
                         side effects for patients.

                         Subcutaneously
                         NanoZolid® can be injected subcutaneously allowing for sustained release of active
                         drugs over an extended period of time for systematic impact and improved
                         compliance.

       ✓          THE TECHNOLOGY IS CLINICALLY PROVEN WITH VALIDATED EFFECTS DURING 6 MONTHS IN PHASE II CLINICALS

5
MANAGEMENT PRESENTATION - Monica Wallter, CEO - Lidds
Strong benefits for both patients and pharma industry

                                PATIENTS                                                 PHARMA INDUSTRY

    Improved efficacy                                               Improved products
    ‒ Higher drug effects in diseased area                          ‒ NanoZolid® enables higher efficiency, compliance and reduced
                                                                      side effects

    Less side effects                                               Prolonged patent protection
    ‒ Minimal and controlled concentration of drug systemically –   ‒ NanoZolid technology maintains competiveness with patents
      improving Quality Of Life                                       until 2037
                                                                    ‒ Opportunity for Life Cycle Management

    Less injections                                                 Re-open closed projects
    ‒ The sustained and controlled drug release gives higher        ‒ Previously closed projects due to severe side effect or too fast
      compliance and Quality Of Life                                  release of the drug can be re-opened

6
MANAGEMENT PRESENTATION - Monica Wallter, CEO - Lidds
NanoZolid® – a clinically validated technology
     A safe, flexible and functional method of delivering drugs as a long-acting depot
     ▪       Intratumoral drug delivery enables a high drug load and efficacy in cancer tumors
             combined with small risks for systemic adverse effects - quality of life for patients
     ▪       Effectively reduces the number of treatments and adverse effects which in turn
             reduces patient discomfort, improves compliance and reduces costs

         NanoZolid® is formulated with APIs with different size & characteristics:
         ▪    Anti-androgens: 2-hydroxy-flutamide & other anti-androgen drugs
         ▪    Cytotoxic drugs: Docetaxel, Doxorubicin, Cisplatin, Temozolamide & other
              cytostatics
         ▪    Immuno-active agents: STING-agonists, TLR- agonists, IDO1-inhibitors
         ▪    Hormones: i.e Testosterone
         ▪    Glucocorticoids
         ▪    Antihistamines
         ▪    Polypeptides

7
Patent protection until year 2037

                                 1
                                     ANTI ANDROGENS – PROSTATECANCER
                                     NZ-2-HOF
                                     Liproca® Depot, 2-hydroxy-flutamide

                                 2
                                     CYTOTOXICS – SOLID TUMORS
               NANOZOLID®            NZ-DTX , NZ-DOX etc
            PATENT PORTFOLIO         Docetaxel, doxorubicin and other cytotoxic drugs

             8 patent families   3
               & 90 patents           IMMUNO-ONCOLOGY
                                      NZ-IO-STING, NZ-IO-TLR9, NZ-IO-003, NZ-IO-004
                                      Immuno-active molecules

                                 4
                                      EXTERNAL PARTNERSHIP – NZ
                                      A wide range of indications are possible

8
LIDDS’ business model

                               1                                  2                                   3                                             4

        PROVEN DRUG                         NANOZOLID®                          INNOVATIVE                            LICENSE
         SUBSTANCE                          TECHNOLOGY                           PRODUCT                            AGREEMENTS

     Off patent or new API               Validated in Phase II                  Local injection                Strategic partnerships
                                           enables optimal                                                     Typically in pre-clinical phase or
                                            product design                                                                 Phase I/II

     LIDDS’ business strategy is to use the NanoZolid® technology for three purposes: in-house drug development, for outlicensing to other
        pharma companies for use in their development of new drugs, and as a tool for life cycle management of established medicines.

9
Overview of current development pipeline
                                                                                                     OUT-LICENSING &
       PROJECT         TARGET             FEASIBILITY   PRECLINICAL   PHASE I / II   PHASE IIb        AGREEMENTS

       In-house drug development
                                                                                                 Out-licensed to China - Licensing
       NZ-2-HOF        Prostate cancer        ✓            ✓              ✓          2017-2019   to ROW during / after Phase IIb

       NZ- DTX         Malignant tumors       ✓            ✓              ✓                      Out-licensing after Phase I

                                                                                                 Out-licensing after preclinical
       NZ-IO- STING    Malignant tumors       ✓            ✓                                     phase

       NZ-IO-TLR9      Malignant tumors       ✓            ✓                                     Out-licensing after Phase I

       NZ-IO-003-004   Malignant tumors       ✓

       NZ-DOX          Malignant tumors       ✓

        NanoZolid® constitutes the bedrock for building a broad portfolio of pharmaceutical projects,
                  which diversifies risk and provides good prospects for future revenue

10
Table of content

                        1.   Introduction to LIDDS

                        2.
                        2.   NanoZolid® with 2-HOF – Prostate cancer

                        3.   NanoZolid® with cytostatics (DTX)

                        4.   NanoZolid® for immunotherapy (IO)

                        5.   NanoZolid® with STING-agonist

                        6.   NanoZolid® with TLR9 agonist

                        A.   Appendix
11
NZ- 2-HOF

     LIDDS treats prostate cancer
     locally
     ▪ Clinical studies shows Liproca® Depot has enhanced
       effects at higher doses, without the hormonal side
       effects that are common with oral treatment.

     ▪ Phase I/II clinical trials with Liproca ®Depot is reported in
       57 patients with good results on PSA biomarker, tumor
       tissue and prostate volume

     ▪ Industrial scale production - NZ-2-HOF at Recipharm

     ▪ LPC-004 status- Safety and tolerability confirmed after
       Part I - entered into Part II in Q3/18

     ▪   Phase IIb study ongoing – results in mid 2019
         ▪ Out-licensed to China
         ▪ Out-licensing to ROW during / after Phase IIb

12
NZ- 2-HOF

     Local treatment strategy
                 Traditional systematic treatment                         Treatment with LIDDS

                     ALL BODY EXPOSED                        LIDDS TARGETS ONLY THE ORGAN
      Chemical castration & anti androgen therapy side   LIDDS’ drug candidate is injected directly into the
      effects:                                           tumour
      ▪   Loss of libido & Erectile dysfunction          ▪ Provides a pre-determined, controlled and long-term effect on
      ▪   Hot flushes                                      the tumour
      ▪   Gynaecomastia and breast pain
      ▪   Increase in body fat & Muscle wasting
      ▪   Anemia
      ▪   Decrease in bone mineral density                 Side effects are fully avoided or significantly reduced
      ▪   Cognitive decline

13
NZ- 2-HOF

     PSA reduction %: LIDDS dose/effect prediction in Phase
     Ilb study based on previous studies
     n = 60 patients with local prostate cancer

                  LPC-002 (700mg) 6 months

                  LPC-0031 (900mg) 2 months

                  LPC-0032 (1,700mg) 2 months

                  LPC-004 (2,000mg) simulated

                  LPC-004 (4,000mg) simulated

14
NZ- 2-HOF

                         The global prostate cancer drug market is
                         estimated to ≥ 8 billion USD in 2022

                                    1,300,000                                                                                                                 Global prostate cancer market

                                    Patients diagnosed per year1
                                                                                                                                                               $8.3bn        in 20234

                                    Every fifth man
                                    Will be diagnosed 20302

                                                                                                                                                                           5%
                                    250,000                                                                                                                               patient share

                                                                                                                                                                 Liproca® Depot yearly sales:
                                    Dies every            year3                                                                                                      ≥ $1,000m

15   Source: (1) World Cancer Research Fund, 2018, (2) Cancer Research UK, (3) Prostate Smart, (4) PharmaPoint: Prostate Cancer - Global Drug Forecast and Market Analysis to 2023.
Table of content

                        1.   Introduction to LIDDS

                        2.   NanoZolid® with 2-HOF – Prostate cancer

                        3.
                        3.   NanoZolid® with cytostatics (DTX)

                        4.   NanoZolid® for immunotherapy (IO)

                        5.   NanoZolid® with STING-agonist

                        6.   NanoZolid® with TLR9 agonist

                        A.   Appendix
16
NZ- DTX

     Lung cancer and solid tumors

     Preclinical study shows that NZ-DTX is as
     efficient as systemic docetaxel in reducing
     tumor growth but with far less side effects

     ▪ Docetaxel is a commonly used chemotherapy: Breast,
       head and neck, gastric, prostate and non small cell lung
       cancer (NSCLC).

     ▪ Monotherapy or in combination with different drugs to
       optimize effects:

     -   Neoadjuvant NZ-DTX before surgery/radiation
     -   Treatment at diagnosis of tumor
     -   Palliative therapy
     -   Combination with systemic drugs, e.g. cytostatics / I-O
     -   Phase I Study started 2019, Scandinavian sites

17
NZ- DTX

                        Promising potential of a focal treatment with
                        docetaxel in non-small cell lung cancer & solid tumors

                                            Lung cancer                                                                                                    310,000
                                                                                              230,000                                                      Diagnosed in

                                         $37bn                                               Diagnosed in US2                                                 EU283

                                          global market1

                                               CAGR of

                                          >13%
                                             until 20231

                                                         >540,000 individuals are diagnosed with lung cancer in the EU28 and the US

18   Source: (1) Lung Cancer Market Research Report – Global Forecast to 2023; (2) American Cancer Society, 2018; (3) Lung Cancer Europe, GLOBOCAN 2012.
Table of content

                        1.   Introduction to LIDDS

                        2.   NanoZolid® with 2-HOF – Prostate cancer

                        3.   NanoZolid® with cytostatics (DTX)

                        4.
                        4.   NanoZolid® for immunotherapy (IO)

                        5.   NanoZolid® with STING-agonist

                        6.   NanoZolid® with TLR9 agonist

                        A.   Appendix
19
NZ-IO

     Immuno Oncology (IO) – a major
     opportunity for LIDDS

     Providing an intratumoral sustained release
     immuno-modulating treatment that increases
     response rates while minimizing side-effects

     Several preclinical projects ongoing, including
     NZ-STING and NZ-TLR9

20
NZ-IO

     Intratumoral Immunotherapy: Acting locally for
     systemic efficacy

                                   INTRATUMORAL INJECTION

     Local treatment                                        Distal effects
     Intratumoral injection with                            Systemic anti-tumor
     Nanozolid formulated drug                              immunity in non-injected
     to stimulate immunity                                  tumors

21
NZ-IO

     Providing a local immuno-modulating treatment that
     increases response rates while minimizing side-effects

                                                                                          COMBINATION THERAPY
                                                                                             IS THE FUTURE
                                                                                        “Emphasis on combination strategies
                                                                                        continues to resonate throughout the
                                                                                          scientific community and has been
                                                                                             highlighted at several recent
      PERCENTAGE SURVIVAL

                                                                                         conferences. During Immunotherapy
                                                                        Immunotherapy     World (January 2017), it was even
                                                                        combination     stated that the field would ultimately
                                                  Increased response
                                                  rates and long-term                      move “entirely” to combination
                                                  survival                                             therapies.”
                                                                                                 - Erin Newburn MS, PhD
                                                                        Immunotherapy
                                                                        monotherapy
                                                                                            The future of these drugs is in
                                                                                        combination strategies […] And, most
                                        Increased long-
                                                                        Traditional       of the data that are leaking out of
                                        term survival                   therapies       ASCO and other meetings are looking
                                                                                                   at combinations.
                                                                                         - Benjamin P. Levy, Clinical Director of
                                                                        Control         Medical Oncology at Kimmel Cancer Centre
                            TIME FROM TREATMENT

22
NZ-IO

     Intratumoral Immunotherapy:
     Leveraging the potential with NanoZolid®

23
NZ-IO

     Intratumoral Immunotherapy
     ▪ Local, intratumoral immunotherapy enables the use of potent immune
       stimulating agents (e.g. STING agonists, TLR-agonists) that can be
       combined with check point inhibitors or other IO drugs
     ▪ Local immune stimulation can induce systemic anti-tumor immunity
     ▪ Possibility to turn “cold tumors” into “hot tumors” that can respond to
       checkpoint inhibition treatment
     ▪ NanoZolid ® formulated local acting immunotherapies offers greater
       treatment options, higher efficacy, increased patient friendliness and
       greater healthcare penetration
     ▪ Enables treatment of deep-lying tumors which can be more
       immunologically representative of primary and metastasizing tumors
       (e.g. lung, brain, colon, prostate, gastric cancers etc.)
     ▪ NanoZolid ® technology enables the potential of intratumoral
       immuno-therapy by providing a practical, efficacious and patient-
       friendly drug delivery technology

24
Table of content

                        1.   Introduction to LIDDS

                        2.   NanoZolid® with 2-HOF – Prostate cancer

                        3.   NanoZolid® with cytostatics (DTX)

                        4.   NanoZolid® for immunotherapy (IO)

                        5.
                        5.   NanoZolid® with STING-agonist

                        6.   NanoZolid® with TLR9 agonist

                        A.   Appendix
25
NZ-STING

     NanoZolid® - STING (NZ-STING)

     STING - Stimulator of interferon genes
      ▪ Highly promising agent for immune stimulation
      ▪ Local activation of STING in tumors leads to potent tumor regression
         and systemic immunity
      ▪ Activators of STING have the potential to make more cancers respond
         to immunotherapy
      ▪ Actively pursued by BMS, Merck, GSK, Novartis and others
      ▪ STING must be administered intratumorally due to severe systemic
         side effects

26
NZ-STING

     Working hypothesis

     ▪ STING agonist treatment is effective when administered in the right
       way
     ▪ For better safety:
        • A slow (and controlled) intratumoral release resulting in low risk
           for systemic side effects
        • Fewer injections avoid risks for complications
     ▪ NanoZolid formulations makes STING agonists practical for treatment:
        • Single injection active up to several months
        • Especially important for tumors not suitable for multiple injections
        • NanoZolid depot is visible with x-ray and ultra sound equipment to
           confirm correct injection
        • Reduced cost for treating hospitals
        • Better patient compliance and convenience
     ▪ Major commercial opportunity

27
NZ-STING

     NZ-STING- extensive preclinical programme
     Syngeneic preclinical animal models were used at a qualified
     European CRO:
     A single NZ-STING injection was equal or better to reduce tumor
     growth versus three repeated standard STING injections
      ▪ Verified efficacy in different syngeneic models
      ▪ Safe and well tolerated
      ▪ Potential to leverage NanoZolid® technology in highly
        competitive and promising field
      ▪ Patent application submitted for NZ-STING

28
Table of content

                        1.   Introduction to LIDDS

                        2.   NanoZolid® with 2-HOF – Prostate cancer

                        3.   NanoZolid® with cytostatics (DTX)

                        4.   NanoZolid® for immunotherapy (IO)

                        5.   NanoZolid® with STING-agonist

                        6.
                        6.   NanoZolid® with TLR9 agonist

                        A.   Appendix
29
NZ-IO-TLR9

     TLR9 agonist project ongoing and plan for Phase I

     ▪ LIDDS has performed pre-clinical studies with promising results using a
       TLR9 agonist formulated with NanoZolid®

     ▪ A preclinical programme is ongoing to broaden the results obtained to
       date

     ▪ Currently preparing for a Phase I clinical trial using NanoZolid®
       combined with a TLR9 agonist

            ▪ Planned start for clinical Phase I trial in 2020

     ▪ Major commercial opportunity
          ▪ The most relevant target cancers for the TLR9 project are head
              and neck cancer, prostate cancer and lymphomas. These cancers
              are diagnosed in around 2 million patients each year.

30
NZ-IO-
                                                                                    STING/TLR9

     Local immunotherapy with NanoZolid® provides
     several advantages vs standard injections

        Standard STING/TLR9-injection                  NanoZolid STING/TLR9 depot
        ˣ Frequent injections                         ✓Up to once every 3 to 6 months

        ˣ Superficial tumors                    Vs.   ✓Superficial and deep-lying
                                                       tumors
        ˣ Limited patient population eligible
                                                      ✓Greater options regarding
                                                       treatment and including poor
        ˣ Limited tumor residence time
                                                       status patients
        ˣ Includes high costs and resources           ✓Long-term immune stimulation
          in specialized hospitals
                                                      ✓Less costs and resources needed

31
Significant value inflection points ahead
             EXPECTED Q1 2019 – Q2 2019              EXPECTED Q3 2019 – Q4 2019

      ▪ Start of Phase I study NZ- DTX-001    ▪ Concluding the Phase IIb study
     ✓  and first patient in
                                              ▪ Update on NZ-DTX-001
      ▪ Preclinical research program NZ-IO-
        STING                                 ▪ Update of NZ-IO projects

      ▪ Preclinical studies NZ-IO- 002-004    ▪ New NZ-projects

      ▪ Status update of NZ-2HOF, LPC-004                  EXPECTED 2020

      ▪ Organization Expansion                ▪ Listing of the company’s shares on
                                                Nasdaq Stockholm’s Main Market

32
Table of content

                        1.   Introduction to LIDDS

                        2.   NanoZolid® with 2-HOF – Prostate cancer

                        3.   NanoZolid® with cytostatics (DTX)

                        4.   NanoZolid® for immunotherapy (IO)

                        5.   NanoZolid® with STING-agonist

                        6.   NanoZolid® with TLR9 agonist

                        A.
                        A.   Appendix
33
A. APPENDIX

     Shareholder list
      Shareholders as per 31 December 2018                        Number of shares       Capital       Votes
      Wikow Ventures AB (Lars Wikander)                                    1,955,048      8.48 %       8.46 %
      Daniel Lifveredson through companies                                 1,914,393      8.30 %       7.63 %
      Nyenburgh Holding B.V.                                               1,521,355      6.60 %       7.01 %
      Bengt Sporre                                                           923,567      4.01 %       4.01 %
      Recipharm Venture Fund AB                                              714,285      3.10 %       3.10 %
      Gunvald Berger                                                         571,258      2.48 %       2.48 %
      BWG Invest Sàrl (William Gunnarsson)                                   531,000      2.30 %       2.32 %
      Henry Dunkers Donationsfond & Stiftelser                               412,314      1.79 %       2.30 %
      Hans Lennernäs with company                                            373,268      1.62 %       1.64 %
      Arena Invest AB (Roberth Emanuelsson)                                  318,471      1.38 %       1.38 %

      Sub total                                                            9,234,959     40.06 %     40.06 %

      Others                                                              13,816,229     59.94 %     59.94 %

      Total                                                               23,051,188     100.0 %     100.0 %

                   SEK

        >200      million
                                    Since LIDDS was founded in 2003, more than SEK 200 million has been invested into the company and the development
                                    of the NanoZolid® technology platform.

34
A. APPENDIX

     Income statement

        (TSEK)                            Oct-Dec 2018 Oct-Dec 2017 Jan-Dec 2018 Jan-Dec 2017

        Other sales                                 0          434         7,763        1,029
        Gross income                                0          434         7,763        1,029

        Other external expenses                 -2,383       -1,561       -6,916       -4,588
        Personnel expenses                        -994       -1,085       -3,150       -3,124
        Impairment of intangible assets         -1,577            0       -1,577            0
        Total costs                             -4,954       -2,646      -11,643       -7,712

        Operating profit                        -4,954       -2,212       -3,880       -6,683

        Financial items                            14            1          133           14

        Profit for the period                   -4,940       -2,211       -3,747       -6,669

35
A. APPENDIX

     Balance sheet

        (TSEK)                          2018-12-31   2017-12-31

        ASSETS

        Fixed assets
        Capitalized development costs     123,002      101,091
        Patent                             12,746       13,189
        Total intangible assets           135,748      114,280

        Total tangible assets                  50            0

        Total fixed assets                135,798      114,280

        Current assets
        Short-term receivables               1,439        1,245
        Cash and cash equivalents           26,139       15,286
        Total current assets                27,578       16,531

        Total assets                      163,376      130,811

        EQUITY AND LIABILITIES
        Equity                            158,517      127,250
        Short-term liabilities              4,859        3,561

        Total equity and liabilities      163,376      130,811

36
A. APPENDIX

     Cash flow statement

        (TSEK)                                         Oct-Dec 2018 Oct-Dec 2017 Jan-Dec 2018 Jan-Dec 2017

        Cash flow from the operating business                -4,297       -1,345       -1,066      -10,715
        Cash flow form investment activities                 -7,097       -4,066      -23,096      -14,079
        Cash flow from financing activities                       0        1,000       35,015       21,399
        Cash flow for the period                            -11,394       -4,411       10,853       -3,395

        Cash position at the beginning of the period        37,533       19,697        15,286       18,681
        Cash position at the end of the period              26,139       15,286        26,139       15,286

37
A. APPENDIX

     Board of directors

                            JAN TÖRNELL                                                                         MARIA FORSS
                            Chairman of the Board since 2015                                                    Board member since 2015
                            Holdings: 33,142 shares, 250,000 warrants                                           Holdings: 18,100 shares, 150,000 warrants

     15 years of experience in executive roles in the pharmaceutical industry in        Master’s degree in Economics from the School of Business, Economics and
     various countries. Professor with medical background. CEO of Oncorena AB           Law and Concordia University, Montreal. Active as VP Business Development
     and AB Innoext. Former Vice President of Global Strategy for AstraZeneca           & Global Marketing at the Swedish listed company Vitrolife since 2012. Maria
     Oncology & Infection. Professor of Physiology at the Sahlgrenska Academy.          Forss has for 20 years worked with product development, business
     Chairman of Glactone Pharma AB and board member of Diaprost AB. Partners           development and marketing of pharmaceutical products in global roles at
     in P.U.L.S. and member of the investment committee. Born 1960.                     AstraZeneca, as well as in the virtual company DuoCort, where she as CEO and
                                                                                        project managers had been instructed to take a new drug from clinical trials
                                                                                        to regulatory approval and sales of the company. She has experience in
                                                                                        product development of medicines from early phase to commercialization,
                                                                                        and from several board positions in the pharmaceutical and medical
                            DANIEL LIFVEREDSON                                          technology companies. Born 1972.
                            Board member since 2017
                            Holdings: 1,759,492 shares, 200,000 warrants

     M.Sc. in Engineering, Industrial Economy, Chalmers tekniska högskola in
     Gothenburg. CEO and owner of Excore AB, specialized in counseling in
     connection with corporate transactions in the segment of medium-sized
     companies. Long experience in international business. Daniel Lifveredson is                                ANDERS BJARTELL
     engaged as a partner in several companies. Born 1976.                                                      Board member since 2015
                                                                                                                Holdings: 18,100 shares, 150,000 warrants

                                                                                        Professor and chief of urology at Skåne University Hospital since 2006. PhD in
                                                                                        Medical cell research. European specialist degree in Urology. Visiting
                                                                                        investigator at Memorial Sloan-Kettering Cancer Center in New York, 2005-
                            INGALILL FORSLUND LARSSON                                   2007. Associate Editor of European Urology, 2005-2012. Responsible for
                            Board member since 2015                                     clinical trials in prostate cancer at the urology clinic SUS Malmö since 2007.
                            Holdings: 10,000 shares, 125,000 warrants                   National Principal Investigator for several new drugs for prostate cancer in
                                                                                        recent years. Research group leader for urological cancer research at the
     Economist with specialization in Marketing from the University of Uppsala. Leg.    Institute for Translational Medicine at Lund University. Published over 200
     Midwife. Many years of sales and marketing responsibility in the                   original scientific articles. H-index 39. Have experience in board work in
     pharmaceutical industry, incl. business responsibility for Urology, Global         European Urology, foundations and life science. Born 1959.
     Marketing at Ferring Pharmaceuticals. several commercial roles at AstraZeneca
     incl. responsible for a number of product launches. Senior Consultant at Lisberg
     Executive Search and Boyden International. CEO of a private real estate and
     consulting company. Board experience from several life science companies.
     Born 1954.

38
A. APPENDIX

     Senior executives and management
                             MONICA WALLTER
                             CEO
                             Holdings: 20,019 shares, 125,000 warrants                                        MARTIN JOHANSSON
     International Diploma in Marketing & Economics from University of Lund,                                  Head of preclinical R&D in immunotherapy
     Sweden. Former CEO of Ellen AB (publ) from 2008 to 2014 and CEO of Probi                                 Holdings: 500 shares, 25,000 warrants
     AB (publ) 2000-2003. Senior international management positions in
     Pharmacia between 1986-1995. Heading several business areas as Global             M.Sc. chemical engineering Lund University, Ph.D. and associate professor in
     Category Director at Pharmacia & Upjohn during 1996-2000.                         organic chemistry at Lund University. 17 years of experience in medicinal
                                                                                       chemistry and preclinical research and development. Formed Chief Scientific
                                                                                       Officer with Respiratorius and senior research scientist at AstraZeneca
                                                                                       Discovery R&D.. Project manager for Glactone Pharma.
                             BENGT NORVIK
                             CFO
                             Holdings: 33,274 shares, 25,000 warrants

     Accountant from the University of Uppsala. Former CFO of Know IT AB (publ),                              MARKUS THOR
     Pargon AB and AB Upnod. Bengt runs his own business Markett                                              Head of Business Development
     Affärsutveckling AB, which provides consulting services in economics and                                 Holdings: 0 shares, 0 warrants
     finance. Bengt has experience from both listed as start-ups in Life Science, IT
     industry and commerce.                                                            MBA from Stockholm School of Economics and M.Sc. in Chemistry from Umeå
                                                                                       University. 25 Years of experience in the pharmaceutical industry with
                                                                                       positions within business development and R&D including Vice President &
                             STEFAN GRUDÉN                                             Head of Business Development at Biovitrum AB, Chief Business Officer at
                                                                                       Kancera AB and Senior Scientist at Pharmacia.
                             Director of pharmaceutical R&D
                             Holdings: 500 shares, 25,000 warrants

     Pharmacists, M.Sc. Pharm., From Uppsala University. 17 years experience in
     pharmaceutical research and development, including 15 years in senior services
     and Pharmacy Manager both Galenica and Orexo. Participated in the                                        CHARLOTTA GAUFFIN
     development of over 50 projects, of which more than a third have been upscaled.
                                                                                                              Head of Clinical Trial Management
                                                                                                              Holdings: 0 shares, 0 warrants
                            NIKLAS AXÉN                                                Master of Science M.Sc. and Ph.D. in organic chemistry from Uppsala University.
                            Director of Biomaterials & Devices                         About 20 years of experience in the pharmaceutical industry, within research
                            Holdings: 70,000 shares, 25,000 warrants                   and clinical development. Has held senior clinical project management
                                                                                       positions at Quintiles and Q-Med/Galderma, with experience from a range of
     M.Sc. Engineering Physics at Uppsala University, PhD and Associate Professor      indications within drug and medical device development.
     of Materials Science at Uppsala University. Niklas Axen has previously worked
     in product development at De Beers and Hemapure, and has been in charge
     of R & D including Cerbio AB, Doxa AB and AB OrtoWay.

39
A. APPENDIX

     Overview of LIDDS’ patent portfolio
       PATENT      PATENT                            US         EU         REST OF THE WORLD

       1 / 2004    Bioceramic compositions           Approved   Approved   Not filed

                                                                           Aus, Can, Chi, Jap, Mex, Russ, S Kor,
       2 / 2006    Method to treat prostate cancer   Approved   Approved
                                                                           Nor, Afr, Isr, Ind,

                                                                           Aus, Can, Chi, HK, Jap, Mex, Russ, S Kor,
       3 / 2007    Slow local drug release           Approved   Approved
                                                                           Isr, S. Afr, Ind,

                                                                           Aus, Can, Chi, Russ, Isr, Jap, Mex, S
       4 / 2009    Mixing tool suspensions           Approved   Approved
                                                                           Korea, Ind, S. Afr

                                                                           Aus, Can, Russ, Jap, HK, Mex, S.Kor, Ind,
       5 / 2009    Steering of curing                Approved   Approved
                                                                           Isr, S. Afr

       6 / 2016    Manufacturing process             Approved   Approved   -

       7 / 2017    NanoZolid + STING                 -          Filed      -

40
Thank you!
     Monica Wallter, CEO
     LIDDS AB
     monica.wallter@liddspharma.com

41
You can also read